FMT plus systemic therapy in renal cell cancer

The PERFORM trial is a prospective clinical study evaluating the impact of fecal microbiota transplantation (FMT) in combination with immune checkpoint inhibitor-based therapy in patients with metastatic renal cell carcinoma. The trial aims to determine whether FMT can enhance treatment efficacy and reduce toxicity by modulating the gut microbiome.